110 related articles for article (PubMed ID: 3521781)
21. Immunohistochemical and immunocytochemical study of bladder carcinomas using the epithelium-specific, tumour-associated monoclonal antibodies HMFG1 and AUA1.
Anagnostaki E; Skarlos D; Tamvakis N; Psaropoulou P; Blana E; Bamias A; Legaki S; Aravantinos G; Deliveliotis C; Dimopoulos K
Br J Cancer Suppl; 1990 Jul; 10():52-6. PubMed ID: 2200496
[TBL] [Abstract][Full Text] [Related]
22. Mining The Cancer Genome Atlas gene expression data for lineage markers in distinguishing bladder urothelial carcinoma and prostate adenocarcinoma.
Ch'ng ES
Sci Rep; 2021 Mar; 11(1):6765. PubMed ID: 33762601
[TBL] [Abstract][Full Text] [Related]
23. Immunoperoxidase staining of acid phosphatase in human prostatic tissue.
Lippert MC; Bensimon H; Javadpour N
J Urol; 1982 Nov; 128(5):1114-6. PubMed ID: 6757466
[TBL] [Abstract][Full Text] [Related]
24. Coordinate expression of cytokeratins 7 and 20 in prostate adenocarcinoma and bladder urothelial carcinoma.
Bassily NH; Vallorosi CJ; Akdas G; Montie JE; Rubin MA
Am J Clin Pathol; 2000 Mar; 113(3):383-8. PubMed ID: 10705819
[TBL] [Abstract][Full Text] [Related]
25. [Immunohistochemical determination of antigen 19-9 (CA 19-9) in transitional carcinoma of the bladder].
Casetta G; Cavallini A; Piana P; Squintone L; Vottero M; Tizzani A
Minerva Urol Nefrol; 1992; 44(3):169-72. PubMed ID: 1492266
[TBL] [Abstract][Full Text] [Related]
26. Monoclonal antibodies to human prostate and bladder tumor-associated antigens.
Starling JJ; Sieg SM; Beckett ML; Schellhammer PF; Ladaga LE; Wright GL
Cancer Res; 1982 Aug; 42(8):3084-9. PubMed ID: 7046915
[TBL] [Abstract][Full Text] [Related]
27. CK5, CK5/6, and double-stains CK7/CK5 and p53/CK5 discriminate in situ vs invasive urothelial cancer in the prostate.
Fichtenbaum EJ; Marsh WL; Zynger DL
Am J Clin Pathol; 2012 Aug; 138(2):190-7. PubMed ID: 22904129
[TBL] [Abstract][Full Text] [Related]
28. Epithelial membrane antigen as an immunohistochemical marker for transitional cell carcinoma of the urinary bladder.
Takashi M; Murase T; Kinjo T; Mitsuya H; Nagura H
Urol Int; 1987; 42(3):170-5. PubMed ID: 3303592
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
[TBL] [Abstract][Full Text] [Related]
30. Carcinoma of the prostate simulating primary bladder cancer.
Amin M; Broghamer W; Amin EA
J Ky Med Assoc; 1990 Jan; 88(1):13-6. PubMed ID: 1688603
[TBL] [Abstract][Full Text] [Related]
31. Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases.
Osunkoya AO; Epstein JI
Am J Surg Pathol; 2007 Sep; 31(9):1323-9. PubMed ID: 17721186
[TBL] [Abstract][Full Text] [Related]
32. Low grade urothelial carcinoma mimicking basal cell hyperplasia and transitional metaplasia in needle prostate biopsy.
Arista-Nasr J; Martinez-Benitez B; Bornstein-Quevedo L; Aguilar-Ayala E; Aleman-Sanchez CN; Ortiz-Bautista R
Int Braz J Urol; 2016; 42(2):247-52. PubMed ID: 27256178
[TBL] [Abstract][Full Text] [Related]
33. Prostatic-specific antigen: clinical experience utilizing immunoperoxidase staining techniques in patients with metastatic prostate cancer.
Baker WC; Meyers FJ; White RW
J Surg Oncol; 1988 Mar; 37(3):165-7. PubMed ID: 2451087
[TBL] [Abstract][Full Text] [Related]
34. Assessment of serum CA 19.9 as a tumour marker in patients with carcinoma of the bladder and prostate.
Abel PD; Cornell C; Buamah PK; Williams G
Br J Urol; 1987 May; 59(5):427-9. PubMed ID: 3474046
[TBL] [Abstract][Full Text] [Related]
35. Benign polyp with prostatic-type epithelium of the urinary bladder: a case report.
Ishikawa J; Yasuno H; Higuchi A; Kamidono S; Okada S
Hinyokika Kiyo; 1990 Dec; 36(12):1463-5. PubMed ID: 1706137
[TBL] [Abstract][Full Text] [Related]
36. [Studies on multiple mucosal biopsy in patients with bladder cancer. 4. Evaluation of Thomsen-Friedenreich antigen in multiple mucosal biopsy and transitional cell carcinoma of the bladder].
Igawa M
Hinyokika Kiyo; 1986 Nov; 32(11):1663-76. PubMed ID: 3825815
[TBL] [Abstract][Full Text] [Related]
37. ABH cell surface isoantigens in invasive bladder carcinoma associated with schistosomiasis.
El Adl MM; Yamase HT; Nieh PT; Mostofa AS; Hinz CF; Walzak MP
J Urol; 1984 Feb; 131(2):249-51. PubMed ID: 6366249
[TBL] [Abstract][Full Text] [Related]
38. Prostatic-specific antigen: an immunohistologic marker for prostatic neoplasms.
Nadji M; Tabei SZ; Castro A; Chu TM; Murphy GP; Wang MC; Morales AR
Cancer; 1981 Sep; 48(5):1229-32. PubMed ID: 6168364
[TBL] [Abstract][Full Text] [Related]
39. Potential value of antisera to epithelial membrane antigen in detecting early invasion in transitional cell carcinoma.
Pocock RD; Ibrahim SK; Sloane JP; Ponder BA; Shearer RJ
Br J Urol; 1983 Dec; 55(6):670-5. PubMed ID: 6652437
[TBL] [Abstract][Full Text] [Related]
40. Monoclonal antibodies to detect A, B and H blood group isoantigens in superficial transitional cell carcinoma of the bladder: a means of predicting invasive recurrences.
Stephenson TJ; Williams JL; Gelsthorpe K
Br J Urol; 1985 Apr; 57(2):148-53. PubMed ID: 3886066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
